Clinical Trial Update: Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial compares autologous hematopoietic stem cell transplantation to alemtuzumab, cladribine, or ocrelizumab for relapsing-remitting multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Cladribine (cladribine)
• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Multiple Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING